Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Return on Equity (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Return on Equity data on record, last reported at 0.49% in Q3 2025.

  • For Q3 2025, Return on Equity rose 194.0% year-over-year to 0.49%; the TTM value through Sep 2025 reached 0.49%, up 194.0%, while the annual FY2024 figure was 1.12%, N/A changed from the prior year.
  • Return on Equity reached 0.49% in Q3 2025 per TNXP's latest filing, down from 0.47% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.47% in Q2 2025 and bottomed at 2.43% in Q3 2024.
  • Average Return on Equity over 3 years is 1.2%, with a median of 1.01% recorded in 2023.
  • Peak YoY movement for Return on Equity: dropped -24bps in 2024, then soared 194bps in 2025.
  • A 3-year view of Return on Equity shows it stood at 1.04% in 2023, then decreased by -23bps to 1.28% in 2024, then soared by 61bps to 0.49% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.49% in Q3 2025, 0.47% in Q2 2025, and 0.82% in Q1 2025.